Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers

Table 1 Baseline characteristics of all study patients divided by sustained virological response status n (%)

	SVR12(+) (n = 91)	SVR12(-) (n = 55)	P value	Total1 (n = 146)
Male gender	69 (75.8)	42 (76.4)	0.941	114 (76.0)
Asians	51 (56.0)	31 (56.4)	0.970	86 (57.3)
Caucasians	40 (43.9)	23 (41.8)	0.800	63 (42.0)
Relapsers	62 (68.3)	17 (30.9)	< 0.001	80 (53.3)
Non-responders	18 (19.8)	32 (58.2)	< 0.001	53 (35.3)
Cirrhosis	44 (48.4)	23 (41.8)	0.463	69 (46.0)
IL28B-CC genotype	37 (40.7)	9 (14.5)	0.001	46 (30.7)
IL28B-Non-CC genotype	27 (29.7)	21 (38.2)	0.289	48 (32.0)
Age	52.4 (50.7-54.2)	52.7 (48.6-56.7)	0.636	52.7 (51.1-54.4)
BMI	26.4 (25.0-27.7)	24.6 (22.9-26.3)	0.735	26.1 (24.9-27.4)
Albumin (g/L)	44.4 (42.9-45.7)	44.8 (42.9-45.8)	0.142	44.2 (42.9-45.5)
Total Bilirubin (μmol/dL)	14.2 (10.7-17.7)	10.8 (8.4-13.1)	0.704	13.3 (10.9-15.7)
ALT (U/L)	86.7 (65.2-108.1)	72.4 (47.0-97.9)	0.061	81 (65.4-96.7)
INR	1.03 (1.01-1.06)	1.03 (0.99-1.07)	0.752	1.04 (1.02-1.06)
HCVRNA(× 106 IU/mL)	6.2 (3.9-8.4)	4.5 (1.9-7.1)	0.425	5.5 (3.8-7.1)
Hb (g/L)	14.7 (14.3-15.1)	14.4 (13.5-15.3)	0.743	14.6 (14.2-14.9)
WBC (× 109/L)	7.04 (6.2-7.9)	6.9 (6.02-7.9)	0.839	6.9 (6.4-7.6)
Neutrophil (× 109/L)	3.8 (3.2-4.4)	3.4 (2.9-3.9)	0.922	3.7 (3.2-4.1)
Platelets (× 109/L)	171.2 (149.5-192.9)	195.3 (163.8-226.7)	0.425	177.2 (159.9-194.6)

¹Four patients did not have an HCV RNA test for sustained virological response (SVR) at follow-up week 12, hence could not be classified. Categorical variables are shown as number (%), and continuous data are shown as means (95%CI). Alb: Serum albumin; ALT: Serum alanine aminotransferase; AST: Serum aspartate aminotransferase; LDH: Lactate dehydrogenase; RNA: HCV RNA; HCV: Hepatitis C virus.